Ascentage Pharma Group International
AAPG | NASDAQ
$15.86
+$0.80 (+5.31%)
At close: Sep 21, 2026, 4:00 PM ET
$15.82
-$0.04 (-0.25%)
After-hours:
Sep 21, 2026, 7:30 PM ET
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q4 2025 Dec 30, 2025 | Q2 2025 Jun 29, 2025 | Q4 2024 Dec 30, 2024 | Q2 2024 Jun 29, 2024 | Q4 2023 Dec 30, 2023 | Q2 2023 Jun 29, 2023 | Q4 2022 Dec 30, 2022 | Q2 2022 Jun 29, 2022 | Q4 2021 Dec 30, 2021 | Q2 2021 Jun 29, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 633.01M | 567.83M | 390.6M | 980.65M | 903.03M | 221.98M | 247.56M | 209.71M | 119.8M | 27.91M | 19.19M |
Cost of Revenue | 116.7M | 90.34M | 35.68M | 29.09M | 27.45M | 30.54M | 29.15M | 22M | 11.74M | 3.33M | 3.57M |
Gross Profit | 516.31M | 477.5M | 354.93M | 951.57M | 875.58M | 191.44M | 218.4M | 187.71M | 108.06M | 24.58M | 15.62M |
Operating Income | -1.38B | -1.19B | -1.12B | -378.8M | -344.08M | -872.64M | -765.47M | -849.81M | -859.82M | -869.84M | -766.89M |
Interest Income | 85.37M | 53.39M | 5.04M | 1.43M | n/a | 32.41M | 37.27M | 9.73M | 8.42M | 7.11M | 6.16M |
Pretax Income | -1.43B | -1.22B | -1.14B | -395.26M | -370.36M | -932.86M | -843.19M | -887.17M | -859.71M | -790.5M | -712.1M |
Net Income | -1.45B | -1.23B | -1.16B | -405.43M | -360.28M | -925.64M | -843.81M | -882.92M | -832.67M | -782.42M | -730.02M |
Selling & General & Admin | 634.8M | 556.26M | 443.97M | 383.12M | 378.43M | 376.46M | 338.67M | 328.02M | 259.64M | 191.26M | 127.66M |
Research & Development | 1.27B | 1.12B | 1.03B | 947.25M | 841.24M | 706.97M | 681.37M | 743.1M | 754.8M | 766.49M | 665.53M |
Other Expenses | n/a | n/a | n/a | -2K | -2K | -19.36M | -36.16M | -33.6M | -48.47M | -63.34M | -8.77M |
Operating Expenses | 1.9B | 1.67B | 1.48B | 1.33B | 1.22B | 1.06B | 983.88M | 1.04B | 965.97M | 894.42M | 784.42M |
Interest Expense | 52.3M | 25.79M | n/a | 28.04M | 48.32M | 96.06M | 102.17M | 52.79M | 34.76M | 16.73M | 11.49M |
Selling & Marketing Expenses | n/a | 137.79M | 244.15M | 196M | 201.71M | 195.39M | 162.03M | 157.42M | 102.58M | 47.75M | 24.56M |
Cost & Expenses | 2.02B | 1.76B | 1.51B | 1.36B | 1.25B | 1.09B | 1.01B | 1.06B | 1.1B | 961.08M | 732.85M |
Income Tax Expense | 14.88M | 6.91M | 15.87M | 10.43M | -9.83M | -7.15M | 622K | -4.25M | -27.04M | -49.83M | -23.83M |
Shares Outstanding (Basic) | 93.31M | 92.6M | 85.37M | 78.09M | 74.01M | 72.51M | 17.64M | 16.48M | 16.48M | 15.91M | 15.91M |
Shares Outstanding (Diluted) | 93.31M | 92.6M | 85.4M | 78.09M | 74.01M | 72.51M | 17.64M | 16.48M | 16.48M | 15.91M | 15.91M |
EPS (Basic) | -15.60 | -13.84 | -14.20 | -5.08 | -5 | -52.48 | -72.08 | -53.60 | -51.36 | -49.12 | -49.68 |
EPS (Diluted) | -15.60 | -13.84 | -14.20 | -5.08 | -5 | -52.48 | -72.08 | -53.60 | -51.36 | -49.12 | -49.68 |
EBITDA | -1.3B | -1.11B | -1.04B | -298.87M | -263.09M | -743.61M | -663.57M | -825.26M | -818.19M | -811.13M | -738.17M |
EBIT | -1.38B | -1.19B | -1.12B | -378.8M | -344.08M | -836.81M | -721.93M | -834.39M | -824.95M | -815.52M | -742.36M |
Depreciation & Amortization | 84.78M | 81.87M | 78.3M | 79.94M | 81M | 93.2M | 58.36M | 9.13M | 6.76M | 4.39M | 4.18M |
Add to Watchlist
Select watchlists to add or remove AAPG